What Receptor Does Ketamine Bind To?
Last reviewed and updated: June 17, 2026.
Key Takeaways
| Primary receptor | NMDA (N-methyl-D-aspartate) glutamate receptor — non-competitive open-channel blocker |
| Secondary receptors | Opioid receptors (analgesic effect), sigma receptors, AMPA modulation — but NMDA is the primary target for both anesthesia and antidepressant effects |
| Antidepressant mechanism | NMDA blockade on prefrontal inhibitory interneurons → BDNF release → mTOR-driven synaptogenesis → new synaptic connections outlasting the drug |
| Esketamine vs. racemic | Esketamine (Spravato) has ~2× NMDA affinity vs. racemic ketamine; (R)-ketamine has additional sigma receptor activity |
| HNK metabolite | Active metabolite (2R,6R)-HNK may have independent antidepressant effects without dissociation — major active research target |
Ketamine, like all drugs, achieves its effects by binding to receptors in the brain. So which receptor does ketamine bind to? Well, there isn’t actually just one that ketamine affects. There are multiple. That being said, ketamine is a common NMDA receptor antagonist (meaning it inhibits its activity). The binding of ketamine to NMDA receptors is crucial for its effects.
Let’s examine the binding of ketamine to NMDA receptors and the various changes that follow from this activity. It will also be helpful to take a look at the other receptors that ketamine binds to, as these also play an important role in the effects of ketamine.
Looking for ketamine therapy? Click here to find top rated ketamine clinics near you
How Ketamine Affects The NMDA Receptor
When ketamine binds to the NMDA receptor, it has quite a paradoxical effect. As an NMDA antagonist, the compound blocks the receptor, yet this produces an increase in brain levels of glutamate. This increase in glutamate levels also seems to be responsible for the wide-ranging effects of ketamine.
It is important, however, that this surge in glutamate is often in low doses. High (anesthetic) doses of ketamine block glutamate neurotransmission (which is when brain cells pass glutamate between each other). Sub-anesthetic doses of ketamine, in contrast, result in the blocking of NMDA receptors, along with the paradoxical increase in glutamate neurotransmission.
ALSO READ: What Is MDA? Everything To Know About The ‘Love Drug’
Ketamine Binding To NDMA Is Central To Its Effects
The burst of glutamate from ketamine’s binding to NMDA receptors is crucial for the drug’s varying effects.
NMDA And The Subjective Effects Of Ketamine
Ketamine’s binding to NMDA receptors causes the transient subjective effects of ketamine, namely the dissociative effects, which can feature the following.
- Visual and auditory distortions or hallucinations
- A sense of floating outside of your body
- Feeling detached from your environment or self
- Disorientation
- Confusion
NMDA And Mental Disorders
The binding of ketamine to the NDMA receptors is also responsible for the therapeutic effects of the compound. NMDA receptors often play a role in mental disorders, such as major depression, anxiety, and addiction. NMDA receptor antagonists, including ketamine, are also known to improve these conditions.
One proposed explanation for ketamine’s therapeutic effects is that the drug increases glutamate, via its binding to NMDA receptors, in areas of the brain with deficits in synaptic connections. This is the ‘glutamate surge’ hypothesis.
Patients with depression and post-traumatic stress disorder (PTSD) have lower brain volume in areas of the brain such as the prefrontal cortex, anterior cingulate cortex, and hippocampus. Researchers state this is likely due, in part, to the loss of synapses.
Looking for ketamine therapy? Click here to find top rated ketamine clinics near you
The prefrontal cortex plays a critical role in our mental health; it contributes to a variety of functions, such as the below.
- Focusing one’s attention
- Predicting the consequences of one’s actions
- Impulse control
- Managing emotional reactions
RELATED: What Does Ketamine Feel Like?
Ketamine And Other Receptors
As mentioned previously, ketamine binds to others receptors in the brain, which also helps to explain the effects of this compound.
Ketamine Binds To Serotonin Receptors
In the brains of people with depression, there is a low density of serotonin 1B receptors, a type of receptor that the neurotransmitter serotonin binds to. A 2020 study published in Translational Psychiatry found that ketamine may alleviate treatment-resistant depression due to its interaction with this particular serotonin receptor.
As New Atlas reports on the findings:
“The study suggests this ketamine-induced binding of serotonin 1B receptors increases the release of dopamine, while reducing levels of serotonin. This newly discovered mechanism of ketamine is hypothesized to play a role in the overall therapeutic benefits of the drug.”
Through this binding, ketamine increases the number of serotonin 1B receptors, which helps to boost dopamine in the brain. This is important in the context of depression, as a decrease in dopamine is associated with depressive-like behaviors. Contrary, increases of this neurotransmitter can help prevent such behaviors. Researchers have tied a deficit in dopamine to depressive symptoms like anhedonia (the inability to feel pleasure) and a lack of motivation.
Clinic Spotlight: Relievus Pain Management – Philadelphia, Pennsylvania
Ketamine Binds To Opioid Receptors
Ketamine also binds to opioids receptors in the brain. The authors of a 2018 study published in the American Journal of Psychiatry state the following:
“Ketamine’s acute antidepressant effect appears to require opioid system activation. Dissociative effects of ketamine in humans are not mediated by the opioid system, nor do they appear sufficient without the opioid effect to produce the acute antidepressant effects of ketamine in adults with treatment-resistant depression.”
If this is true, then it is not just the subjective effects of ketamine that contribute to its therapeutic potential. Studies have revealed that the quality of the ketamine experience predicts improvements in depression. But it may be that the mystical-type effects of ketamine are not the only relevant factor in treating mental disorders. Ketamine might lead to better clinical outcomes through its effects on receptors that are not involved in the drug’s subjective effects.
What The NMDA Discovery Means For Depression Treatment
Ketamine’s relationship to the NMDA receptor has taken on new significance since researchers began understanding why it works so rapidly as an antidepressant. For decades, depression treatment was built around the serotonin hypothesis — SSRIs block serotonin reuptake, gradually building up synaptic serotonin levels over 4–6 weeks. Ketamine’s mechanism is fundamentally different and its timeline is dramatically faster: robust antidepressant effects can appear within hours to a day of a single infusion.
The BDNF hypothesis. NMDA blockade by ketamine triggers an unusual downstream effect: a rapid, large release of BDNF (brain-derived neurotrophic factor) — sometimes called “Miracle-Gro for the brain.” BDNF activates TrkB receptors and the mTOR signaling pathway, which promotes synaptogenesis (formation of new synaptic connections) in the prefrontal cortex. In people with depression, the prefrontal cortex has measurably fewer and weaker synaptic connections — a result of chronic stress, glucocorticoid exposure, and the atrophic effects of persistent depression itself. The mTOR-driven synaptogenesis may explain both the rapid effect and the durability of relief: new synaptic connections take time to degrade, which is why a single ketamine infusion can produce benefit lasting days to weeks despite the drug clearing the body in hours.
The disinhibition model. A competing (and potentially complementary) explanation involves the inhibitory interneurons in the prefrontal cortex. These GABAergic interneurons express high levels of NMDA receptors. When ketamine blocks NMDA on these inhibitory cells, it silences them — paradoxically increasing excitatory activity in the prefrontal cortex overall. This burst of excitatory activity may itself trigger BDNF release and the downstream plasticity. This “disinhibition” model helps explain why the timing of NMDA blockade matters and why the antidepressant effect can outlast the drug.
HNK and the active metabolite question. One of the more surprising recent findings is that (2R,6R)-hydroxynorketamine (HNK), a metabolite of ketamine produced in the liver, may have independent antidepressant effects that don’t require NMDA blockade or dissociative side effects. If this holds in human trials, it opens the possibility of ketamine-derived drugs without the psychedelic component — a significant pharmacological target that multiple pharmaceutical companies are currently investigating.
Frequently Asked Questions
What receptor does ketamine primarily bind to?
Ketamine is primarily a non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist. It enters the NMDA receptor ion channel when the channel is open and blocks it from the inside — the “open channel block” mechanism. NMDA receptors are ionotropic glutamate receptors that regulate calcium ion flow and play central roles in synaptic plasticity, memory formation, and neural development. Ketamine blocks these receptors across the brain, which accounts for its anesthetic, analgesic, dissociative, and antidepressant effects. At sub-anesthetic doses, NMDA blockade in specific circuits — particularly GABAergic interneurons in the prefrontal cortex — drives the antidepressant effect.
Why does NMDA antagonism produce antidepressant effects so rapidly?
The leading explanation involves ketamine triggering a rapid release of BDNF (brain-derived neurotrophic factor) and activating the mTOR signaling pathway, which promotes synaptogenesis — growth of new synaptic connections — in the prefrontal cortex. People with depression have measurably reduced synaptic density in the prefrontal cortex; ketamine’s mTOR-driven plasticity may rapidly reverse this deficit. A second mechanism is disinhibition: ketamine blocks NMDA receptors on inhibitory interneurons, which paradoxically increases excitatory activity in the prefrontal cortex and may itself trigger BDNF release. Both mechanisms may act together. The critical point is that these downstream effects outlast the drug — which clears the body in hours — because new synaptic connections persist. This explains how a 40-minute infusion can produce benefit lasting days to weeks.
Does ketamine damage NMDA receptors?
At therapeutic doses used in clinical settings (typically 0.5 mg/kg IV, administered in supervised sessions), there is no evidence of persistent NMDA receptor damage. NMDA blockade by ketamine is reversible — it dissociates from the channel as concentrations decline. The concerns about NMDA-related neurotoxicity (Olney’s lesions) were observed in animal models at very high repeated doses and have not been replicated at clinical therapeutic doses in human studies. The risks associated with long-term heavy recreational ketamine use — including cognitive impairment and ketamine-induced ulcerative cystitis (bladder syndrome) — are distinct from therapeutic protocol risks and are associated with much higher doses, more frequent use, and the absence of medical supervision.
What’s the difference in receptor activity between ketamine and Spravato (esketamine)?
Both target the NMDA receptor, but with differences in binding affinity and pharmacokinetics. Esketamine (the (S)-enantiomer) has approximately 3–4× higher affinity for the NMDA receptor than (R)-ketamine, and roughly twice the affinity of racemic ketamine overall. This means esketamine produces similar effects at lower concentrations. The (R)-enantiomer also has sigma receptor activity that esketamine doesn’t share, which may contribute to the slightly different experiential profile some patients report between racemic IV ketamine and intranasal Spravato. Both compounds are metabolized to hydroxynorketamine (HNK) metabolites, which are under investigation as independent therapeutic agents without dissociative effects.
